Irish Principal Investigator
This important study is led in Ireland by Professor Fran Duane, Consultant Radiation Oncologist at SLRON.
The E²-RADIatE registry study is a large, international research project led by the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO). It is open at:
St. Luke’s Radiation Oncology Network (SLRON)
The Beacon Hospital
University Hospital Galway (UHG)
What is this study about?
E²-RADIatE is a non-interventional registry study. That means patients do not receive any new or experimental treatments. Instead, the study collects real-world data on how patients with cancer are treated with radiotherapy and how they respond in terms of cancer treatment and the short and long-term side-effects of their treatment.
The goal is to understand:
- How radiotherapy is used in everyday clinical practice,
- How patients are selected for different treatments,
- What the outcomes are (including side effects and quality of life),
- How to safely improve radiotherapy for future patients.
Two different patient groups (cohorts) are part of this registry
1. OligoCare Cohort
For patients with oligometastatic cancer – this means cancer that has spread to only a few sites (typically five or fewer), where treatment is still being given with a radical (curative) intent.
You may be eligible if you:
- Have breast, prostate, colorectal or non-small cell lung cancer,
- Have a limited number of metastases (typically five or fewer),
- Are receiving radical radiotherapy to at least one cancer site of spread.
2. ReCare Cohort
For patients who are being treated with high-dose re-irradiation—that is, having radiotherapy to a part of the body that has already received radiation in the past.
You may be eligible if you:
- Are having radiotherapy to a part of the body that has already received radiation in the past.
- Are receiving this treatment as part of your standard care.
What’s involved for patients?
This is an observational study, so taking part:
- Does not change your treatment plan,
- Does not require extra hospital visits,
- Does not involve any experimental treatment.
If you agree to participate:
- The study team will collect information from your medical records (e.g. type of cancer, treatments received, imaging, and outcomes),
- You may be asked to complete quality of life questionnaires during and after your radiotherapy,
- Some data on healthcare use (e.g. hospital visits or medications) may also be collected.
All your personal information is stored securely and managed in line with GDPR and Irish data protection laws.
Why are registry studies important?
While clinical trials are vital, they often include only select groups of patients. Registry studies like E²-RADIatE:
- Include a broader, more realistic range of patients,
- Help researchers understand how treatments work in everyday practice,
- Identify what works best, for whom, and when,
- Can lead to improved safety standards, treatment guidelines, and better outcomes,
- Support development of safer and more effective use of radiation therapy.
They are especially valuable in areas like:
- Oligometastatic cancer, where local treatment approaches (like SABR) are expanding,
- Re-irradiation, where guidance on safe dose limits is still evolving.
Trial status in Ireland
The E²-RADIatE registry study is:
- Open at St. Luke’s Radiation Oncology Network (SLRON)
- Open at The Beacon Hospital
- Open at University Hospital Galway (UHG)
So far:
- X patients have been enrolled in the OligoCare cohort
- X patients have been enrolled in the ReCare cohort
These numbers will be updated as the study progresses.